Actavis expands manufacturing site in Iceland
Production at Actavis Hafnarfjordur site, Iceland
The Hafnarfjordur, Iceland manufacturing site exports 95% of its products. After expansion the SOD-site‘s capacity will be about 1.5 billion tablets pr. year, depending on the mix of products. Production is expected to start at the new facility by year end 2010, with no disruption to current manufacturing capabilities.
The site produces many of Actavis‘ latest generics and specialises in new product launches. Actavis hf in Iceland currently employs about 300 people, mostly in production and quality. By the end of this year, 50 new jobs will be created following the expansion. Actavis Group employs over 10,000 people in 40 countries, including about 570 in Iceland.
The Hafnarfjordur site is ISO 14001 and OHSAS 18001 certified and runs on sustainable energy; electricity from hydropower and geothermal heating. Actavis remains committed to its environmental, health and safety performance, with 11 of its manufacturing sites ISO 14001 certified, seven with an OHSAS 18001 certification.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.